课题基金 / 基金详情

RANDOMIZED DOUBLE-BLIND PHASE II STUDY OF INDINAVIR SULFATE, DMP-266 AND 1592U

RANDOMIZED DOUBLE-BLIND PHASE II STUDY OF INDINAVIR SULFATE, DMP-266 AND 1592U
硫酸茚地那韦、DMP-266 和 1592U 的随机双盲 II 期研究
批准号:
6297812
负责人:
MARGRIT CARLSON
金额:
$0.19万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

MARGRIT CARLSON的其他基金

相似基金

相关文献

中文摘要
翻译
ACTG 320是一项抗HIV药物的临床试验, 使用三种药物组合齐多夫定(ZDV)+茚地那韦(IDV), 联合用药(ZDV + 3TC),在既往服用过 齐多夫定 三种药物组合包括两种药物 与两种药物组合相比, 只有一种新药 这项研究表明,这三种药物 组合更有效。
英文摘要
ACTG 320 was a clinical trial of anti-HIV medications which compared the use of a three drug combination Zidovudine (ZDV)+Indinavir(IDV) to a two drug combination (ZDV + 3TC), in persons who ahd previously taken Zidovudine ZDV. The three drug combination included two medications that were potent and new, as compared to the two drug combination which had only one new drug. This study showed that the three drug combination was more effective.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A PHASE II STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF QUADRIVALENT: HIV
FLUCONAZOLE AS CHRONIC SUPPRESSIVE VS EPISODIC THERAPY IN HIV PATIENT
COMPARISON OF THE VIROLOGIC EFFECACY OF NELFINAVIR AND/OR DMP-266 IN COMBINATION
ANTIVIRAL ACTIVITY OF T 20 ADMINISTERED TO HIV 1 POSITIVE ADULTS
海外基金